Key Highlights
- Juliana Blum, PhD, named CEO of BioAesthetics, effective August 12, 2024.
- Blum brings 20 years of biotech experience, notably as Co-founder of Humacyte.
- Focus on advancing BioAesthetics’ next-gen drug-eluting graft technology for soft tissue reconstruction.
Source: Business Wire
Notable Quotes
- “This is an important milestone for BioAesthetics… Dr. Blum’s experience with novel products as co-founder of Humacyte will help guide further progress at BioAesthetics.” — Dr. Sandra Coufal, MD, Director of BioAesthetics and CEO at Toragen, Inc
- “I am thrilled to join the BioAesthetics team… There is a strong foundation for future growth and innovation around this novel platform that I look forward to leading.” — Dr. Juliana Blum, CEO at BioAesthetics
- “Dr. Blum has a proven reputation for developing and managing partnerships… This experience is critical for the future growth of BioAesthetics.” — Joseph Nixon, MBA, Director of BioAesthetics and CFO at Locus Biosciences, Inc
SoHC's Take
The appointment of Dr. Juliana Blum as the new CEO of BioAesthetics marks a pivotal moment for the company as it transitions from a phase of foundational growth to one of strategic commercialization. Dr. Blum’s extensive background in leading biotech innovations from concept through commercialization, particularly her work with Humacyte, positions her as a strong leader to advance BioAesthetics’ cutting-edge drug-eluting graft technology. Her expertise in global regulatory affairs, manufacturing scale-up, and partnership development will be crucial as BioAesthetics seeks to bring its novel products to market and solidify its position in the regenerative medicine space. This leadership change is not just a milestone but a clear signal of the company’s commitment to scaling its operations and impacting the field of reconstructive care.
